Mechanisms underlying T-cell tolerance

Current Opinion in Immunology

Volumn 8, Issue 2, 1996, Pages 233-244

  Kruisbeek, Ada M ^a   Amsen, Derk ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; T LYMPHOCYTE RECEPTOR;

IMMUNOLOGICAL TOLERANCE; PERIPHERAL LYMPHOCYTE; REVIEW; T LYMPHOCYTE; THYMUS;

EID: 0029888844     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80062-8     Document Type: Article

References (111)

1. Janeway CA Jr: Thymic selection: two pathways to life and two to death. Immunity 1994, 1:3-6.
2. Jameson SC, Bevan MJ: T cell receptor antagonists and partial agonists. Immunity 1995, 2:1-11.
3. k. Proc Natl Acad Sci USA 1994, 91:12463-12466.
4. k form and dissociate rapidly at neutral pH. J Immunol 1995, 154:5216-5227.
5. Fairchild PJ, Thorpe CJ, Travers PJ, Wraith DC: Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immuotherapy of autoimmune disease. Immunology 1994, 81:487-496.
6. •].
7. Joosten I, Wauben MHM, Holewijn MC, Reske K, Pedersen LF, Roosenboom CFP, Hensen EJ, Van Eden W, Buus S: Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int Immunol 1994, 6:751-759.
8. •] provide key evidence that low-avidity interactions between developing thymocytes and agonist peptide-MHC complexes allow escape from central tolerance, and that such 'escapes' can appear as functionally competent T cells in the periphery.
9. Davis CB, Littman DR: Thymocyte lineage commitment: is it instructed or stochastic? Curr Opin Immunol 1994, 6:266-272.
10. Carlow DA, Van Oers NSC, Teh SJ, Teh HS: Deletion of antigen-specific immature thymocytes by dendritic cells requires LFA-1/ICAM interactions. J Immunol 1992, 148:1595-1603.
11. Mueller DL, Jenkins MK: Molecular mechanisms underlying functional T-cell unresponsiveness. Curr Opin Immunol 1995, 7:375-381.
12. •], these findings set the stage for the notion that CTLA-4 plays an important role in quenching T-cell responses.
13. •] by demonstrating that blockade of either CTLA-4 or B7-1/2 in vitro augments anti-CD28 induced costimulation. CTLA-4 can no longer be regarded as a redundant receptor for B7-1/2; indeed, it achieves an effect opposite to that of CD28.
14. Linsley PS: Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation. J Exp Med 1995, 182:289-292.
15. Sethna PM, Van Parijs L, Sharpe AH, Abbas AK, Freeman GJ: A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity 1994, 1:415-421.
16. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 1995, 155:1032-1036.
17. •].
18. •] provide a dramatic demonstration of an in vivo role of CTLA-4 in maintaining homoeostasis: gene-targeted mice lacking CTLA-4 progressively accumulate T-cell blasts in both lymphoid and non-lymphoid organs, and die at 3-4 weeks of age as a result of severe tissue destruction.
19. + thymocytes. J Immunol 1993, 151:1868-1880.
20. •]).
21. + thymocytes. J Immunol 1992, 149:3217-3224.
22. Jones LA, Izon DJ, Nieland JD, Linsley PS, Kruisbeek AM: CD28-B7 interactions are not required for intrathymic clonal deletion. Int Immunol 1993, 5:503-512.
23. Lucas PJ, Negishi I, Nakayama K-I, Fields LE, Loh DY: Naive CD28-deficient T cells can initiate, but not sustain an in vitro antigen-specific immune response. J Immunol 1995, 154:5757-5768.
24. Walunas TL, Spelin Al, Khattri R, Thompson CB, Bluestone JA: CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance. J Immunol 1996, 181:485-491.
25. Berg LJ, Pullen AM, Fazekas de St Groth B, Mathis D, Benoist C, Davis MM: Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell 1989, 58:1035-1046.
26. + T cells by transgenic I-E restricted to thymic medullary epithelium. J Immunol 1993, 151:3954-3960.
27. + thymocytes. J Immunol 1994, 152:3254-3263.
28. Foy TM, Page DM, Waldschmidt TJ, Schoneveld A, Laman JD, Masters SR, Tygrett L, Ledbetter JA, Aruffo A, Claassen E et al.: An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med 1995, 182:1377-1388. Presents comprehensive support for the notion that gp39-CD40 interactions provide costimulatory signals for thymocyte deletion; these interactions may operate through the up-regulation of B7-1 and/or B7-2 on thymic stromal cells.
29. Galy AHM, Spits H: CD40 is functionally expressed on human thymic epithelium. J Immunol 1992, 149:775-782.
30. Foy TM, Durie FH, Noelle RJ: The expansive role of CD40 and its ligand in immunity. Semin Immunol 1994, 6:259-266.
31. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R: Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995, 25:596-603.
32. Kennedy MK, Mohler KM, Shanebeck KD, Baum PR, Picha KS, Otten-Evans CA: Janeway CA Jr, Grabstein KH: Induction of B cell costimulatory function by recombinant murine CD40 ligand. Eur J Immunol 1994, 24:116-123.
33. + T lymphocytes. J Immunol 1994, 152:1523-1531.
34. Wu Y, Xu J, Shinde S, Grewal I, Henderson T, Flavell RA, Liu Y: Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 1990, 5:1303-1311.
35. Van Essen D, Kikutani H, Gray D: CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 1995; 378:620-623.
36. Grewal IS, Xu J, Flavell RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995, 378:617-620.
37. Jones LA, Chin LT, Longo DL, Kruisbeek AM; Peripheral clonal elimination of functional T cells. Science 1990, 250:1726-1729.
38. Webb S, Morris C, Sprent J: Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990, 63:1249-1256.
39. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 1991, 349:245-247.
40. Rocha B, Von Boehmer H: Peripheral selection of the T cell repertoire. Science 1991, 251:1225-1228.
41. Moskophidis D, Lechner F, Pircher H, Zinkernagel R: Virus persistence in acutely infected immunocompetent mice by exhaoustion of antiviral cytotoxic effector T cells. Nature 1993, 362:728-761.
42. Huang L, Crispe IN: Superantigen-driven peripheral deletion of T cells. Apoptosis occurs in cells that have lost the α/β T cell receptor. J Immunol 1993, 151:1844-1851.
43. Kyburz D, Aichele P, Speiser DE, Hengartner H, Zinkernagel RM, Pircher H: T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptldes. Eur J Immunol 1993, 23:1956-1962.
44. D'Adamio L, Awad KM, Reinherz EL: Thymic and peripheral apoptosis of antigen-specific T cells might cooperate in establishing self tolerance. Eur J Immunol 1993, 23:747-753.
45. Critchfield JM, Racke MK, Zúniga-Pflücker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ: T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994, 263:1139-1142.
46. Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN: The liver eliminates T cell undergoing antigen-triggered apoptosis in vivo. Immunity 1994, 1:741-749. Provides solid evidence that a large proportion of T cells in which apoptosis has been induced is eliminated in the liver.
47. Kearney ER, Papte KA, Loh DY, Jenkins MK: Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994, 1:327-339.
48. Sprent, J, Webb SR: Intrathymic and extrathymic clonal deletion of T cells. Curr Opin Immunol 1995, 7:196-205. A very thoughtful review on both intrathymic and extrathymic clonal deletion, with the emphasis placed on the variables that dictate the outcome of the response.
49. 51chromium. Cell Immunol 1976, 21:278-302.
50. Wahl C, Miethke T, Heeg, K, Wagner H: Clonal deletion as direct consequence of an in vivo T cells response to bacterial superantigen. Eur J Immunol 1993, 23:1197-1200.
51. Miethke T, Wahl C, Gaus G, Heeg K, and Wagner H: Exogenous superantigens acutely trigger distinct levels of peripheral T cell tolerance/immuno-supression: dose-response relationship. Eur J Immunol 1994, 24:1893-1902.
52. •]) and, presumably, clearance by macrophages, certain sensitive methods will reveal their presence.
53. + T cell deletion. Immunity 1995, 3:321-333.
54. + cells. J Immunol 1994, 132:4270-4281.
55. Zal T, Volkmann A, Stockinger B: Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 1994, 180:2089-2099.
56. Salmon M, Pilling D, Borthwick NJ, Viner N, Janossy G, Bacon PA, Akbar AN: The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis. Eur J Immunol 1994, 24:892-699.
57. + T cells specific for a pancreatic β cell neo-antigen. Immunity 1995, 2:573-585.
58. Rocha B, Grandien A, Freitas AA: Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med 1995, 181:993-1003.
59. Ravzi ES, Welsh RM, McFarland HI: In vivo state of antiviral CTL precursors: characterization of a cycling cell population containing CTL precursors in immune mice. J Immunol 1995, 154:620-632.
60. Walker PR, Ohteki T, Lopez JA, MacDonald HR, Maryanski JL: Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol 1995, 155:3443-3452.
61. Crispe IN: Fatal interactions: Fas-induced apoptosis of mature T cells. Immunity 1994, 1:347-349.
62. Watanabe R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 386:314-316.
63. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliverative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
64. + thymocytes are susceptible to Fas-induced apoptosis [111], yet lpr mice exhibit no obvious defect in thymic deletion [71].
65. •].
66. •] document the association of defects in Fas with a human lymphoproliferative syndrome, which in some individuals is also associated with autoimmune disorders. These studies are particularly relevant because they reveal that, in contrast to the lpt, multiple different Fas gene mutations can be responsible for a defect in apoptosis.
67. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995, 181:71-77.
68. Ito N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-243.
69. Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH: Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995, 373:438-441.
70. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Decheverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995, 373:441-444.
71. Singer CG, Abbas AK: The Fas antigen is involved in peripheral but not thymlc deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994, 1:365-371.
72. Ju S-T, Panka DJ, Cul H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373:444-446.
73. + effector T cells that threaten the integrity of the graft?
74. + T lymphocytes that enter the eye are triggered to undergo FasL-dependent apoptosis and produce no tissue damage. In contrast, severe invasion of ocular tissue is observed in eyes of gld mice (which lack functional FasL) under such conditions.
75. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995, 16:39-43.
76. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995, 377:348-352. With the aim of understanding the observation that the ability of mature T cells from lpr and gld mice to undergo apoptotic cell death is not completely obliterated, these authors demonstrate that TNF can mediate Fas-independent mature T-cell apoptosis. Mediation involves the p75 TNF receptor, and a suggestion is made that Fas and TNF receptor act on non-overlapping T-cell populations.
77. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, Biron CA: Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticolds. J Exp Med 1995, 181:901-914.
78. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray GS, Nadler LM: CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995, 92:811-815.
79. Klas C, Debatin K-M, Jonker RR, Krammer PH: Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993, 5:625-630.
80. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N: Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992, 149:3753-3758.
81. L. Immunity 1995, 3:87-98.
82. Hughes DPM, Crispe IN: A naturally occurring soluble isoform of murine Fas generated by alternative splicing. J Exp Med 1995, 182:1395-1401.
83. Miller JFAP, Heath WR: Self-ignorance in the peripheral T-cell pool. Immunol Rev 1993, 133:131-150.
84. DeSilva DR, Urdahl KB, Jenkins MK: Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991, 147:3261-3267.
85. c chain of the IL-2 receptor. Science 1994, 266:1039-1042.
86. Arnold B, Schönrich G, Hämmerling GJ: Multiple levels of peripheral tolerance. Immunol Today 1993, 14:12-14.
87. Ferber I, Schönrich G, Schenkel J, Mellor AL, Hämmerling GJ, Arnold B: Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994, 263:674-676.
88. b for the duration of the pregnancy. T-cell responsiveness was restored after delivery.
89. Delassus S, Coutinho GC, Saucier C, Darche S, Kourilsky P: Differential cytokine expression in maternal blood and placenta during murine gestation. J Immunol 1994, 152:2411-2420.
90. Guerder S, Meyerhoff J, Flavell R: The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994, 1:155-166.
91. Ohashi PL, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkemagel RM, Hengartner H: Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
92. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
93. Harian DM, Hengartner H, Huang ML, Kang Y-H, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ et al.: Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoproteln-speclfic transgenic T cells develop diabetes due to a break-down of T-lymphocyte unresponsiveness. Proc Natl Acad Sci USA 1994, 91:3137-3141.
94. Geiger T, Gooding LR, Flavell RA: T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc Natl Aacd Sci USA 1992, 89:2985-2989.
95. Brethscher P, Cohn M: A theory of self-nonself discrimination. Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 1970, 169:1042-1049.
96. Kündig TM, Bachmann MF, DiPaolo C, Simard JJL, Battegay M Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, Zinkernagel RM: Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1346.
97. Doherty PC: Anatomical environment as a determinant in viral immunity. J Immunol 1995, 155:1023-1027.
98. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1189. This paper makes the point that the concept of protection from diabetes development in NOD mice resulting from suppression of nocuous Th1 responses by Th2 cells may be too simplistic. Although Th2-like responses have been found correlated with protection from diabetes in this study, skewed injected Th2 cell lines were incapable of preventing disease induction by Th1 cell lines.
99. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, McDevitt HO, Lo D; A role for non-MHC genetic polymorphism in susceptibility to spontaneous autoimmunity. Immunity 1994, 1:73-82.
100. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK: An altered peptide ligand mediates immune deviation and prevents autoimmune encephalo-myelitis. Immunity 1995, 3:397-405.
101. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995, 16:34-38.
102. Finkelman FD: Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 1995, 182:279-282.
103. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
104. Wogensen L, Lee M-S, Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cell in nonobese diabetic mice. J Exp Med 1994, 179:1379-1384.
105. Chen Y, Kuchroo VK, Inobe J-i, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1241. Provides evidence that upon feeding mice a low-dose MBP, tolerance can result from induction of a regulatory set of cells. These regulatory cells may not be classical Th2 cells, as the protective activity depended on TGFβ production by these cells.
106. Chen Y, Inobe J-i, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995, 376:177-180.
107. Kuchroo VK, Das MP, Brown JA, Ranger AM, Aamvil SC, Sobel RA. Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718.
108. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Erp Med 1995, 181:1145-1155.
109. Hirokawa M, Kitabayashi, A, Kuroki J, Miura AB: Signal transductlon by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunology 1995, 86:155-161.
110. Windhagen A, Scholz C, Höllsberg P, Fukaura H, Sette A, Hafler DA: Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995, 2:373-380.
111. + thymocytes by anti-Fas antibody. J Exp Med 1995, 181:486-491.